Journal
CLINICAL RHEUMATOLOGY
Volume 40, Issue 5, Pages 2071-2073Publisher
SPRINGER LONDON LTD
DOI: 10.1007/s10067-020-05364-1
Keywords
Biologics; Henoch-Schonlein purpura; IL-17; Psoriatic arthritis; Rheumatology; Secukinumab
Categories
Ask authors/readers for more resources
Psoriatic arthritis, a chronic seronegative spondyloarthropathy associated with psoriasis, is treated with various options ranging from non-pharmacologic measures to biologics. Secukinumab, a human monoclonal antibody targeting interleukin-17, has shown high effectiveness in treating this condition. However, clinicians should be aware of potential rare adverse events, such as Henoch-Schonlein purpura vasculitis, that may be induced by anti-IL17 treatment.
Psoriatic arthritis is a chronic, seronegative spondyloarthropathy associated with psoriasis, depending on patient presentation treatment options range from non-pharmacologic measures to NSAIDs, DMARDs, and biologics. Secukinumab is a human monoclonal antibody that specifically targets interleukin-17 and has been shown to be highly effective in the treatment of psoriatic arthritis. As the use of IL-17 inhibitors has been approved in the treatment of psoriatic arthritis, clinicians need to be aware of unusual adverse events not previously observed in clinical trials. We report a rare case of Henoch-Schonlein purpura vasculitis induced by secukinumab in a 39-year-old patient. Therefore, using biologic drugs in clinical practice should be aware that cutaneous vasculitis may be triggered by anti-IL17 treatment, and early diagnosis always helps to decrease morbidity and reduce the amount of time to recovery as well as the impact on the quality of life disruption.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available